FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2133755890> ?p ?o ?g. }

• W2133755890 abstract "Colorectal cancer is a common malignancy in Europe with approximately 150 000 new cases and 60 000 deaths every year. In Italy, 30 000 new cases are expected annually [1]. Survival for colorectal cancer increased in all European countries from 44% (1986–1989) to 52% (1992–1994), improving equally for men and women, younger and older patients, and rectal and colonic sites. Geographic disparities between European regions persisted according to the results of EUROCARE-3 [2]. It could be that part of the increase in colorectal survival is due to early diagnoses, increase in the resection rate, a decrease in post-operative mortality and finally an increase in the use of adjuvant treatments. This paper discusses the modalities available for adjuvant treatment of high risk colon cancer patients. Surgery is the primary curative treatment of colon cancer, although a high number of patients develop recurrence despite appropriate local therapy. The most important prognostic factor in anticipating the risk of recurrence is the lymph-nodes (LN) involvement at the time of resection. In stage II (LN-) the risk of relapse ranges from roughly 25 –30% and 40 –60% for stage III (LN+).Survival is influenced not only by the presence of positive LN, but also by the number. Wong et al. reported that patients with LN- had significantly fewer LN examined than did node+ patients (14 versus 20 LN) [3]. Le Voyer et al. reported that 5-yr survival was 73% in stage II, if 10 or fewer LN were recovered, whereas that number improved to 87%, an absolute 14% improvement in survival, if more than 20 LN were recovered. At least 14 LN should be examined to accurately stage a patient with colon cancer [4]. The tumour relapses occur in sites distant from the primary tumor: liver, peritoneum, lung and bone. Seventy-four percent of recurrence occurs within the first 3-years. Adjuvant therapy aims to eliminate this residual disease and to increase the disease free interval and overall survival (OS). Approximately 40% of patients are candidates for adjuvant chemotherapy because LN+, while there is a 15 –20% of patients with LNin which there is a large variability in indication for adjuvant treatment." @default.
• W2133755890 created "2016-06-24" @default.
• W2133755890 creator A5023215623 @default.
• W2133755890 creator A5041135391 @default.
• W2133755890 date "2005-05-01" @default.
• W2133755890 modified "2023-10-05" @default.
• W2133755890 title "Adjuvant therapy in colon cancer: which treatment in 2005?" @default.
• W2133755890 cites W1774247546 @default.
• W2133755890 cites W1870066362 @default.
• W2133755890 cites W1984887866 @default.
• W2133755890 cites W2010397777 @default.
• W2133755890 cites W2040212812 @default.
• W2133755890 cites W2084753380 @default.
• W2133755890 cites W2097132235 @default.
• W2133755890 cites W2121368761 @default.
• W2133755890 cites W2126191931 @default.
• W2133755890 cites W2140626944 @default.
• W2133755890 cites W2141768150 @default.
• W2133755890 cites W2147212583 @default.
• W2133755890 cites W2151725006 @default.
• W2133755890 cites W2152851361 @default.
• W2133755890 cites W2157769714 @default.
• W2133755890 cites W2161367377 @default.
• W2133755890 cites W2168377135 @default.
• W2133755890 cites W2171232394 @default.
• W2133755890 cites W2172116130 @default.
• W2133755890 cites W2230119135 @default.
• W2133755890 cites W2240879185 @default.
• W2133755890 cites W2248563460 @default.
• W2133755890 cites W2255487108 @default.
• W2133755890 cites W2299554685 @default.
• W2133755890 cites W2313857605 @default.
• W2133755890 cites W2319127039 @default.
• W2133755890 cites W2338448884 @default.
• W2133755890 cites W2408136432 @default.
• W2133755890 cites W598519044 @default.
• W2133755890 doi "https://doi.org/10.1093/annonc/mdi911" @default.
• W2133755890 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15923433" @default.
• W2133755890 hasPublicationYear "2005" @default.
• W2133755890 type Work @default.
• W2133755890 sameAs 2133755890 @default.
• W2133755890 citedByCount "1" @default.
• W2133755890 countsByYear W21337558902012 @default.
• W2133755890 crossrefType "journal-article" @default.
• W2133755890 hasAuthorship W2133755890A5023215623 @default.
• W2133755890 hasAuthorship W2133755890A5041135391 @default.
• W2133755890 hasBestOaLocation W21337558901 @default.
• W2133755890 hasConcept C121608353 @default.
• W2133755890 hasConcept C126322002 @default.
• W2133755890 hasConcept C143998085 @default.
• W2133755890 hasConcept C2777863537 @default.
• W2133755890 hasConcept C2777982462 @default.
• W2133755890 hasConcept C526805850 @default.
• W2133755890 hasConcept C71924100 @default.
• W2133755890 hasConceptScore W2133755890C121608353 @default.
• W2133755890 hasConceptScore W2133755890C126322002 @default.
• W2133755890 hasConceptScore W2133755890C143998085 @default.
• W2133755890 hasConceptScore W2133755890C2777863537 @default.
• W2133755890 hasConceptScore W2133755890C2777982462 @default.
• W2133755890 hasConceptScore W2133755890C526805850 @default.
• W2133755890 hasConceptScore W2133755890C71924100 @default.
• W2133755890 hasLocation W21337558901 @default.
• W2133755890 hasLocation W21337558902 @default.
• W2133755890 hasOpenAccess W2133755890 @default.
• W2133755890 hasPrimaryLocation W21337558901 @default.
• W2133755890 hasRelatedWork W130560434 @default.
• W2133755890 hasRelatedWork W2051447115 @default.
• W2133755890 hasRelatedWork W2054423421 @default.
• W2133755890 hasRelatedWork W2075088688 @default.
• W2133755890 hasRelatedWork W2096393323 @default.
• W2133755890 hasRelatedWork W2414195948 @default.
• W2133755890 hasRelatedWork W2419639504 @default.
• W2133755890 hasRelatedWork W2484025090 @default.
• W2133755890 hasRelatedWork W4220654808 @default.
• W2133755890 hasRelatedWork W4367319693 @default.
• W2133755890 isParatext "false" @default.
• W2133755890 isRetracted "false" @default.
• W2133755890 magId "2133755890" @default.
• W2133755890 workType "article" @default.